Lawmakers have focused on the high cost of diabetes drugs. The announcement will make state-branded insulin available two ...

PARIS, France, June 9, 2012-- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Lantus (insulin glargine) is a brand-name prescription drug used to treat diabetes. As with other medications, Lantus can interact with alcohol and certain other drugs. An interaction occurs when one ...

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

Eli Lilly and Co., announced Wednesday that it will reduce the price of insulin and cap the monthly cost to most of its insulin users at $35 starting in May, putting the life saving drug within reach ...

Eli Lilly announced it will automatically cap out-of-pocket (OOP) costs at $35 at participating retail pharmacies for Americans with commercial insurance using some of its insulin products. Eli Lilly ...

Lawmakers have focused on the high cost of diabetes drugs. The announcement will make state-branded insulin available two ...